Enter Your Details Below

Get Investor Fraud News Updates


May 23, 2025

Organon Lawsuit Submission Form
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon’s priorities, particularly, related to cap...
Learn More
According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon’s priorities, particularly, related to capital allocation through quarterly dividends. Notably, defendants concealed the high priority of Organon’s debt reduction strategy following the Company’s acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. Following this news, the price of Organon’s common stock declined dramatically. From a closing market price of $12.93 per share on April 30, 2025, Organon’s stock price fell to $9.45 per share on May 1, 2025, a decline of more than 27% in the span of just a single day.

Active Cases

Ticker Symbol Company Name Join Deadline Join
NSSC Napco Security Technologies, Inc. June 24, 2025 Join
NSSC Napco Security Technologies, Inc. June 24, 2025 Join
CODI Compass Group Diversified Holdings, LLC July 08, 2025 Join
IOVA Iovance Biotherapeutics, Inc. July 14, 2025 Join
OGN Organon & Co. July 22, 2025 Join